During the past decade, Sanger Heart and Vascular Institute conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 4 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sanger Heart and Vascular Institute" #1 sponsor was "Abbott Medical Devices" with 3 trials, followed by "Biotronik, Inc." with 2 trials sponsored, "Medtronic Cardiac Rhythm and Heart Failure" with 2 trials sponsored, "W.L.Gore & Associates" with 2 trials sponsored and "Abiomed Inc." with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sanger Heart and Vascular Institute" #1 collaborator was "IQVIA Biotech" with 1 trials as a collaborator, "Ji Xing Pharmaceuticals (Shanghai) Co., Ltd." with 1 trials as a collaborator, "Medpace, Inc." with 1 trials as a collaborator, "Medtronic" with 1 trials as a collaborator and "University of Rochester" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Sanger Heart and Vascular Institute" are "Heart Failure" (5 trials), "Abdominal Aortic Aneurysm (AAA)" (1 trials), "AtrioVentricular Nodal Reentrant Tachycardia" (1 trials), "Cardiomyopathies" (1 trials) and "Coronary Artery Disease" (1 trials). Many other conditions were trialed in "Sanger Heart and Vascular Institute" in a lesser frequency.

Most popular intervention types in "Sanger Heart and Vascular Institute" are "Device" (15 trials), "Drug" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Arena Strive" (1 trials), "CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)" (1 trials), "Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System" (1 trials), "Cardiac Resynchronization Therapy" (1 trials) and "Cardiac catheter ablation with ICD/CRT-D" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sanger Heart and Vascular Institute" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Sanger Heart and Vascular Institute". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Sanger Heart and Vascular Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Sanger Heart and Vascular Institute, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 9 trials that are defined as “Not Applicable".